Phase 3 Study of MAP0004 in Adult Migraineurs

NCT00623636 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

902

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine Disorders

Interventions

DRUG: MAP0004
DRUG: Placebo

Sponsor

Allergan

Collaborators

[object Object]